China Continuous Glucose Monitoring Market - Strategic Insights and Forecasts (2026-2031)

The China Continuous Glucose Monitoring (CGM) market is forecast to reach USD 1.90 billion in 2031, a significant increase from USD 0.45 billion in 2026. This growth trajectory represents a robust Compound Annual Growth Rate (CAGR) of 33.4% over the forecast period, highlighting immense expansion potential.

The market's growth is predominantly driven by the escalating prevalence of diabetes, particularly Type 2, a heightened awareness and acceptance of CGM technology, and robust government support and policy initiatives. Additionally, increasing disposable income and a growing national focus on healthcare contribute significantly to this upward trend.

The diabetes burden in China is substantial, with 140.87 million individuals aged 20-79 diagnosed with diabetes in 2021, a figure projected to rise to 164.07 million by 2040. This alarming prevalence, coupled with 1.3967 million diabetes-attributable mortality cases in 2021, serves as a critical driver for the demand for advanced monitoring solutions like CGM.

Continuous Glucose Monitoring (CGM) devices are primarily designed to cater to individuals with both type 1 and type 2 diabetes. These wearable medical devices empower 'remote' patients by continuously monitoring blood sugar levels, providing crucial data that can be transmitted to relatives and healthcare providers for timely interventions and improved patient care.

Companies such as SIBIONICS and MicroTech CGMS are highlighted for their significant strides in the China CGM market. SIBIONICS, recognized as the world's third-largest CGMS brand, recently achieved a major milestone by receiving the CE Mark for its revolutionary GS1 CGM, enabling its distribution in the European market. MicroTech CGMS has also proven instrumental in aiding thousands of patients through remote monitoring globally.

Robust government support and specific policy initiatives are identified as crucial drivers fostering the growth and acceptance of CGM technology within China. Concurrently, the increasing disposable income among the Chinese population allows for greater investment in advanced healthcare technologies, thereby contributing significantly to the market's expansion and adoption.